Express Pharma

MARCH 20, 2023

India is preparing to include human papillomavirus (HPV) vaccines as part of the government-driven public immunization program popularly known as the Universal Immunization Program (UIP). The Indian government will float a global tender in April 2023 to procure HPV vaccines. million in 2030. million in 2030.

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

OCTOBER 26, 2020

Strategies include different options focused on health maintenance, such as vaccination programmes, smoking cessation services, support for physical activity, and access to technologies that support early detection of diseases. How could payer views change by 2030? Understanding payer views of preventive care.

Vaccines 130

Vaccines 130

Express Pharma

NOVEMBER 26, 2024

With the Indian pharma market projected to grow to $ 130 billion by 2030 and $ 450 billion by 2047, the event highlighted the industry’s vital role in shaping global healthcare. Projections indicate exports will soar to $130 billion by 2030 and $450 billion by 2047. With exports nearing $27.84 trillion.

Packaging 105

Packaging Biosimilars Pharmaceutical Manufacturing Dosage 105

Express Pharma

AUGUST 27, 2024

Bharat Biotech (BBIL) has launched HILLCHOL (BBV131), an oral cholera vaccine developed under license from Hilleman Laboratories. To meet global demand, Bharat Biotech has established large-scale manufacturing facilities in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses of the vaccine annually.

Vaccines 111

Vaccines 111

Express Pharma

DECEMBER 18, 2024

Additionally, the industry is set to make notable progress in cutting-edge areas such as CAR-T cell therapy, mRNA vaccines, and the development of complex molecules, which hold immense potential for driving future growth. Indian pharma market is expected to move up to USD 120-130 Billion by 2030 from current size of USD 58 Billion.

Biosimilars 98

Biosimilars Vaccines 98

Express Pharma

JANUARY 22, 2024

Cameroon has kickstarted the world’s first routine vaccine programme against malaria. It is one of 20 African countries planning to introduce the drug this year, according to global vaccine alliance Gavi. The vaccine is designed to be administered to young children in four doses from around five months of age.

Vaccines 105

Vaccines 105

European Pharmaceutical Review

OCTOBER 4, 2023

The World Health Organization ( WHO ) has recommended a new vaccine, R21/Matrix-M, to prevent malaria in children. The R21 vaccine is the second malaria vaccine recommended by WHO. This follows the WHO’s recommendation of the RTS,S/AS01 vaccine for the disease in 2021.

Vaccines 111

Vaccines 111

pharmaphorum

JUNE 29, 2022

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Pfizer’s RSVpreF vaccine is in hot pursuit of GSK’s shot, with results due to be reported very soon from the phase 3 RENOIR trial in older adults.

Vaccines 101

Vaccines 101

Express Pharma

DECEMBER 20, 2024

Renowned for its extensive production of generic drugs and vaccines, the sector has played a pivotal role in addressing global healthcare demands. As of 2024, India has produced nearly half of the eight billion vaccine doses distributed worldwide, cementing its reputation as a reliable healthcare contributor.

Biosimilars 103

Biosimilars Vaccines 103

European Pharmaceutical Review

OCTOBER 18, 2022

billion by 2030, according to a market report. However, during the second half, the surge in demand for vaccines to fight the coronavirus enhanced the industry’s need for raw materials and product intermediates of API molecules. billion by 2030 appeared first on European Pharmaceutical Review. billion in 2022 to $14.65

Dosage 105

Dosage Vaccines 105

Express Pharma

DECEMBER 11, 2024

billion in 2030, with the pediatric and adult segments accounting for $2.2 Six more products in late-stage development have potential to launch by 2030. Various unmet needs are expected to be addressed over the forecast period, including more prophylactic options across the different patient segments, as well as combination vaccines.

Vaccines 102

Vaccines Compounding 102

STAT

DECEMBER 13, 2024

Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.

Pharmaceutical Companies 247

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Pricing 247

European Pharmaceutical Review

NOVEMBER 7, 2024

percent between 2025 and 2030. Increasing demand for biopharmaceuticals, “including therapeutic proteins and vaccines, drives the use of rocking bioreactors in cell culture processes”, the reported explained. Key companies profiled in the single-use technology rocking bioreactor market report included Thermo Fisher Scientific Inc.,

Compounding 52

Compounding Vaccines 52

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccines 78

Vaccines Immunity Immunization 78

European Pharmaceutical Review

NOVEMBER 13, 2024

Lenacapavir for PrEP could provide an important alternative to existing preventative medications that require more frequent dosing, and could help transform the HIV prevention landscape by addressing a range of unmet needs for individuals who need or want PrEP globally,” Ogbuagu added.

Vaccines 98

Vaccines 98

European Pharmaceutical Review

AUGUST 3, 2022

To fill the divide, the Joint United Nations Programme on HIV and AIDS (UNAIDS) , the United Nations Children’s Fund (UNICEF), the World Health Organization (WHO) and partners have brought together a global alliance to ensure that no child living with HIV is denied treatment by 2030 – and to prevent new infant HIV infections.

Vaccines 105

Vaccines 105

Express Pharma

JUNE 14, 2024

It is already a massive $50 billion market and is projected to grow to $130 billion by 2030. India makes 60 per cent of the world’s vaccines and 20 per cent of the world’s generic drugs. India’s pharmaceutical industry is a global powerhouse.

Pharmaceutical Companies 110

Pharmaceutical Companies Pharmaceutical Companies Pharmaceutical Manufacturing Packaging 110

Express Pharma

JULY 15, 2024

We believe that implementing a fresh PLI scheme for vaccines and biopharmaceutical raw materials is vital now to put the focus back on value-added domestic production with India-for-India and India-for-the-world production. This would stimulate new investments in both R&D and production initiatives.

Medical Records 105

Medical Records Biosimilars Pharmaceutical Companies Pharmaceutical Companies 105

Express Pharma

JANUARY 4, 2024

The Indian pharma industry is on a solid growth trajectory, surging from $40 billion in 2021 to an estimated $130 billion in 2030, with a steady double-digit CAGR for the next 10 years. It meets 50 per cent of the global demand for various vaccines, 40 per cent of the generic demand in the US, and 25 per cent of all medicine in the UK.

Packaging 111

Packaging Labelling Vaccines 111

European Pharmaceutical Review

SEPTEMBER 7, 2022

billion market by 2030, growing from a 2020 value of around $2.4 New types of drugs, such as oral vaccines, will also be formulated as capsules. Insights on the Empty Capsules Global Market to 2030 – Featuring ACG Worldwide, Bright Pharma Caps and Lonza Among Others [Internet]. About the author. GlobeNewswire News Room.

Dosage 124

Dosage Vaccines Diabetes 124

STAT

JANUARY 12, 2023

SAN FRANCISCO — When BioNTech was founded in 2008, messenger RNA therapies and vaccines were still an unproven idea. The German company has now shipped out billions of doses of its mRNA Covid-19 vaccine worldwide — and BioNTech’s leaders say that’s just the beginning of a larger revolution in medicine.

Vaccines 251

Vaccines 251

European Pharmaceutical Review

AUGUST 21, 2023

billion by 2030 and grow at a CAGR of 3.84 percent from 2023 to 2030. The data stated that expansion of the market in emerging countries is due to factors such as the rising success rate of RNA-based COVID-19 vaccines, regulatory approval, as well as demand for personalised medicines.

Vaccines 98

Vaccines 98

pharmaphorum

JANUARY 15, 2021

Now, speaking to him as the first vaccines are deployed in the UK, he highlights the importance of GSK’s employees and culture to the future of the company post-COVID. With the new goals, GSK aims to have a net zero impact on climate and a net positive impact on nature by 2030.

Drug Development 105

Drug Development Vaccines 105

Express Pharma

JANUARY 12, 2024

With the Indian Pharma sector trying to reach the USD 130 Billion target by 2030, there is a renewed spirit of research in the areas of cell and gene therapy, biologics and biosimilars apart from the already strong generic and vaccine manufacturing sectors of the country.

Biosimilars 105

Biosimilars Vaccines 105

STAT

FEBRUARY 12, 2024

Novo Holdings, the controlling shareholder of Novo Nordisk, plans to invest about $35 billion by 2030 , Reuters writes. Novo Holdings would invest about $5 billion a year in the next five years, and that could go up to $7 billion a year by 2030.

Diabetes 243

Diabetes Vaccines Communication Hospitals 243

Pharma Mirror

OCTOBER 28, 2021

Amsterdam, The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The post CPhI Annual Report 2021: Short term reshoring the catalyst for longer term manufacturing innovations by 2030 appeared first on Pharma Mirror Magazine.

Vaccines 52

Vaccines 52

Express Pharma

FEBRUARY 2, 2024

billion in 2022, and the vision is to achieve the ambitious targets of $150 billion by 2025 and $300 billion by 2030. I would like to emphasise that we have not missed the biotech bus, especially when we contribute 90 per cent of vaccines and pharmaceuticals to the world. I ndia’s biotech industry clocked $92.3

Vaccines 111

Vaccines 111

Pharmaceutical Technology

MARCH 31, 2023

The company will construct the new advanced mRNA facility, which is claimed to be Moderna’s first mRNA manufacturing facility in Africa and is expected to have the capacity to produce up to 500 million vaccine doses annually. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccines 105

Vaccines 105

pharmaphorum

AUGUST 3, 2022

The fall reflects “COVID-19 related rates and severity of infections and hospitalisations, as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19,” said the company.

Vaccines 105

Vaccines 105

Express Pharma

JANUARY 9, 2025

The data will serve as a foundation for cutting-edge research and will catalyse innovations in areas such as mRNA-based vaccines, protein manufacturing, and genetic disorder treatments. The Minister also pointed out that India is the largest vaccine producer in the world and the third-largest startup ecosystem.

Vaccines 105

Vaccines Hospitals 105

pharmaphorum

MARCH 31, 2021

An excellent example of this is COVID-19 vaccine trial data; press releases are eagerly followed in almost real-time by HCPs and the public alike. Q5: ‘Blue-sky thinking’: what will data dissemination look like in 2030? What are the associated challenges?

Communication 98

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

Express Pharma

NOVEMBER 24, 2023

With objectives laid down during the G20 presidency, the industry in India is poised to scale to $65 billion by 2024 and surpass $130 billion by 2030, driven by heightened pharma innovation, technological advancements, and a focus on breakthrough products.

Packaging 105

Packaging Vaccines Pharmaceutical Manufacturing Hospitals 105

Express Pharma

MAY 7, 2024

The report goes on to advise that India’s pharma companies should invest more in developing capabilities to make generic copies of biologics (biogenerics), as more biologics are set to lose exclusivity in the period up to 2030. Biogenerics comes with higher risks, as the manufacturing process and technologies are more complex.

Insurance Coverage and Processing 105

Insurance Coverage and Processing Vaccines Drug Pricing 105

European Pharmaceutical Review

MAY 21, 2025

The collaboration between BioNTech and the UK government focuses on three key areas: accelerating oncology clinical trials for BioNTechs investigational medicines investment to increase BioNTechs UK R&D footprint research into certain areas such as regenerative medicine and infectious disease vaccines.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

pharmaphorum

JANUARY 24, 2023

Where medicines are biologics, such as vaccines, insulin, blood products, and numerous specialty medicines, failsafe cold chains will be necessary from manufacturer to patient. Wholesalers and pharmacies operate under regulations which define storage, supply, and service standards, and these come with energy requirements.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

Express Pharma

JUNE 15, 2024

India, synonymous with the “pharmacy of the world” has rightfully earned the title, owing to its remarkable contribution in supplying 20 per cent of the global generic medicines, along with 60 per cent of the total vaccine demand worldwide. Concurrently, the Indian pharma segment has witnessed steady growth with a CAGR of 9.43

Vaccines 111

Vaccines Generic Medicine 111

pharmaphorum

JUNE 1, 2022

Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.

Vaccines 145

Vaccines Immunity Immunization Hospitals 145